Supplementary Table 1 from PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib
Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, Eugene Lifshits, Andrea J. Gonzales, Takeshi Shimamura, Feng Zhao, Patrick W. Vincent, George N. Naumov, James E. Bradner, Irene W. Althaus, Leena Gandhi, Geoffrey I. Shapiro, James M. Nelson, John V. Heymach, Matthew Meyerson, Kwok‐Kin Wong, Pasi A. Jänne
Cited by 0Open Access
Abstract
Supplementary Table 1 from PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib
Related Papers
No related papers found
Powered by citation graph analysis